Brandon James Sumpio, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Foot | 7 | 2024 | 383 | 2.470 |
Why?
|
| Wound Healing | 10 | 2024 | 2800 | 1.080 |
Why?
|
| Peripheral Arterial Disease | 10 | 2021 | 1304 | 0.890 |
Why?
|
| Diabetes Mellitus, Experimental | 4 | 2024 | 1121 | 0.880 |
Why?
|
| Venous Insufficiency | 2 | 2021 | 109 | 0.820 |
Why?
|
| Bandages | 4 | 2024 | 270 | 0.820 |
Why?
|
| Endovascular Procedures | 12 | 2023 | 2215 | 0.750 |
Why?
|
| Ultrasonography, Doppler, Duplex | 2 | 2021 | 198 | 0.720 |
Why?
|
| Blood Vessel Prosthesis Implantation | 6 | 2023 | 1456 | 0.570 |
Why?
|
| Ischemia | 7 | 2021 | 1905 | 0.550 |
Why?
|
| Diabetes Mellitus | 3 | 2023 | 5887 | 0.510 |
Why?
|
| Lower Extremity | 2 | 2021 | 1217 | 0.490 |
Why?
|
| Vascular Grafting | 3 | 2021 | 163 | 0.470 |
Why?
|
| Vascular Surgical Procedures | 5 | 2021 | 1506 | 0.430 |
Why?
|
| Amputees | 1 | 2013 | 100 | 0.400 |
Why?
|
| Aortic Aneurysm, Abdominal | 4 | 2023 | 1251 | 0.400 |
Why?
|
| Postoperative Care | 2 | 2019 | 1480 | 0.370 |
Why?
|
| Upper Extremity | 1 | 2016 | 684 | 0.360 |
Why?
|
| Molecular Imaging | 1 | 2016 | 822 | 0.320 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2021 | 538 | 0.300 |
Why?
|
| MicroRNAs | 1 | 2024 | 3792 | 0.290 |
Why?
|
| Tibia | 1 | 2013 | 1071 | 0.280 |
Why?
|
| Negative-Pressure Wound Therapy | 2 | 2019 | 156 | 0.270 |
Why?
|
| Intermittent Claudication | 2 | 2019 | 305 | 0.260 |
Why?
|
| Aortic Diseases | 2 | 2022 | 741 | 0.250 |
Why?
|
| Endothelium, Vascular | 1 | 2016 | 4424 | 0.220 |
Why?
|
| Skin | 2 | 2023 | 4499 | 0.220 |
Why?
|
| Raynaud Disease | 1 | 2023 | 81 | 0.200 |
Why?
|
| Scleroderma, Localized | 1 | 2023 | 85 | 0.200 |
Why?
|
| Therapies, Investigational | 1 | 2023 | 110 | 0.200 |
Why?
|
| Mesenteric Veins | 1 | 2021 | 87 | 0.180 |
Why?
|
| Ulcer | 1 | 2021 | 203 | 0.170 |
Why?
|
| Debridement | 1 | 2022 | 494 | 0.170 |
Why?
|
| Endarterectomy | 1 | 2020 | 196 | 0.170 |
Why?
|
| Thrombelastography | 1 | 2022 | 194 | 0.170 |
Why?
|
| Sclerotherapy | 1 | 2021 | 183 | 0.170 |
Why?
|
| Scleroderma, Systemic | 1 | 2023 | 346 | 0.160 |
Why?
|
| Interleukin-10 | 1 | 2024 | 1182 | 0.150 |
Why?
|
| Popliteal Artery | 1 | 2020 | 312 | 0.150 |
Why?
|
| Retrospective Studies | 20 | 2023 | 81635 | 0.150 |
Why?
|
| Patient Readmission | 3 | 2023 | 3283 | 0.150 |
Why?
|
| Rabbits | 1 | 2024 | 4752 | 0.140 |
Why?
|
| Mesenteric Vascular Occlusion | 1 | 2018 | 93 | 0.140 |
Why?
|
| Thrombosis | 2 | 2022 | 2953 | 0.140 |
Why?
|
| Pulsatile Flow | 1 | 2018 | 318 | 0.140 |
Why?
|
| Spectrum Analysis | 2 | 2016 | 443 | 0.140 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 6558 | 0.130 |
Why?
|
| Femoral Artery | 1 | 2020 | 827 | 0.130 |
Why?
|
| Oxyhemoglobins | 1 | 2016 | 213 | 0.120 |
Why?
|
| Treatment Outcome | 17 | 2023 | 65273 | 0.120 |
Why?
|
| Hyperemia | 1 | 2016 | 223 | 0.120 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2019 | 348 | 0.120 |
Why?
|
| Brachial Artery | 1 | 2016 | 373 | 0.120 |
Why?
|
| Nephrotic Syndrome | 1 | 2018 | 381 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 7475 | 0.110 |
Why?
|
| Benchmarking | 1 | 2020 | 1056 | 0.110 |
Why?
|
| Risk Assessment | 9 | 2021 | 24295 | 0.110 |
Why?
|
| Quality Indicators, Health Care | 2 | 2021 | 1804 | 0.110 |
Why?
|
| Time Factors | 12 | 2021 | 40149 | 0.110 |
Why?
|
| Risk Factors | 16 | 2023 | 74881 | 0.110 |
Why?
|
| Perfusion Imaging | 1 | 2014 | 193 | 0.110 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2018 | 540 | 0.110 |
Why?
|
| Celiac Artery | 2 | 2023 | 65 | 0.100 |
Why?
|
| Humans | 37 | 2024 | 766766 | 0.100 |
Why?
|
| Artificial Limbs | 1 | 2014 | 121 | 0.100 |
Why?
|
| Prosthesis Design | 2 | 2022 | 2120 | 0.100 |
Why?
|
| Vasodilation | 1 | 2016 | 969 | 0.100 |
Why?
|
| Neovascularization, Physiologic | 1 | 2019 | 1368 | 0.100 |
Why?
|
| Hospital Costs | 1 | 2018 | 955 | 0.100 |
Why?
|
| Knee | 1 | 2013 | 274 | 0.100 |
Why?
|
| Patient Admission | 1 | 2019 | 1364 | 0.090 |
Why?
|
| Microcirculation | 1 | 2016 | 1282 | 0.090 |
Why?
|
| Oxygen | 1 | 2023 | 4251 | 0.090 |
Why?
|
| Comorbidity | 6 | 2022 | 10580 | 0.090 |
Why?
|
| Aged | 18 | 2024 | 171343 | 0.090 |
Why?
|
| Foot | 1 | 2014 | 576 | 0.090 |
Why?
|
| Male | 23 | 2024 | 364142 | 0.090 |
Why?
|
| Hospital Mortality | 3 | 2019 | 5343 | 0.090 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 59550 | 0.090 |
Why?
|
| Hemoglobins | 1 | 2016 | 1531 | 0.090 |
Why?
|
| Female | 23 | 2024 | 396520 | 0.080 |
Why?
|
| Regional Blood Flow | 3 | 2019 | 1478 | 0.080 |
Why?
|
| Critical Illness | 5 | 2021 | 2750 | 0.080 |
Why?
|
| Databases, Factual | 6 | 2021 | 8066 | 0.080 |
Why?
|
| Surgical Wound Infection | 1 | 2019 | 1547 | 0.080 |
Why?
|
| Phosphoproteins | 1 | 2018 | 2448 | 0.080 |
Why?
|
| Leg | 1 | 2014 | 1087 | 0.080 |
Why?
|
| Postoperative Period | 1 | 2013 | 1824 | 0.080 |
Why?
|
| Constriction, Pathologic | 2 | 2023 | 1103 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2024 | 18330 | 0.070 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2018 | 2902 | 0.070 |
Why?
|
| Limb Salvage | 2 | 2021 | 488 | 0.070 |
Why?
|
| Health Care Costs | 1 | 2021 | 3242 | 0.070 |
Why?
|
| Length of Stay | 2 | 2018 | 6490 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2024 | 15416 | 0.070 |
Why?
|
| Middle Aged | 12 | 2024 | 223257 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2019 | 8728 | 0.070 |
Why?
|
| Blood Vessel Prosthesis | 2 | 2022 | 956 | 0.070 |
Why?
|
| Stents | 1 | 2018 | 3193 | 0.060 |
Why?
|
| Atherosclerosis | 1 | 2021 | 3420 | 0.060 |
Why?
|
| Equipment Design | 1 | 2013 | 3487 | 0.060 |
Why?
|
| Postoperative Complications | 3 | 2023 | 15831 | 0.060 |
Why?
|
| Chemokine CX3CL1 | 1 | 2024 | 61 | 0.060 |
Why?
|
| Interleukin-5 | 1 | 2024 | 268 | 0.050 |
Why?
|
| United States | 9 | 2023 | 72951 | 0.050 |
Why?
|
| Angiography | 2 | 2021 | 1595 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 7431 | 0.050 |
Why?
|
| Electronics | 1 | 2024 | 315 | 0.050 |
Why?
|
| Streptozocin | 1 | 2023 | 189 | 0.050 |
Why?
|
| Animals | 6 | 2024 | 168930 | 0.050 |
Why?
|
| Lactates | 1 | 2023 | 398 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 15908 | 0.050 |
Why?
|
| Elastomers | 1 | 2022 | 69 | 0.050 |
Why?
|
| Interleukin-13 | 1 | 2024 | 391 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2024 | 702 | 0.040 |
Why?
|
| Remission, Spontaneous | 1 | 2021 | 384 | 0.040 |
Why?
|
| Swine | 2 | 2022 | 5987 | 0.040 |
Why?
|
| Prevalence | 3 | 2022 | 15835 | 0.040 |
Why?
|
| Platelet Function Tests | 1 | 2022 | 275 | 0.040 |
Why?
|
| Swine, Miniature | 1 | 2022 | 972 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2024 | 54871 | 0.040 |
Why?
|
| Interleukin-4 | 1 | 2024 | 1155 | 0.040 |
Why?
|
| Prognosis | 4 | 2024 | 29948 | 0.040 |
Why?
|
| Aortography | 1 | 2021 | 423 | 0.040 |
Why?
|
| Budgets | 1 | 2021 | 233 | 0.040 |
Why?
|
| Hospital Bed Capacity | 1 | 2020 | 200 | 0.040 |
Why?
|
| Saphenous Vein | 1 | 2021 | 519 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2011 | 2817 | 0.040 |
Why?
|
| Blood Proteins | 1 | 2024 | 1194 | 0.040 |
Why?
|
| Vascular Patency | 1 | 2021 | 915 | 0.040 |
Why?
|
| Electric Stimulation Therapy | 1 | 2024 | 635 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2016 | 22248 | 0.040 |
Why?
|
| Age Factors | 3 | 2021 | 18397 | 0.040 |
Why?
|
| Water | 1 | 2024 | 1417 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 20144 | 0.040 |
Why?
|
| Splanchnic Circulation | 1 | 2018 | 122 | 0.040 |
Why?
|
| Ankle Brachial Index | 1 | 2018 | 163 | 0.040 |
Why?
|
| Hematoma | 1 | 2022 | 766 | 0.040 |
Why?
|
| Acute Disease | 2 | 2018 | 7241 | 0.040 |
Why?
|
| Cell Shape | 1 | 2018 | 372 | 0.030 |
Why?
|
| Abdominal Pain | 1 | 2023 | 1069 | 0.030 |
Why?
|
| Mice | 4 | 2024 | 81889 | 0.030 |
Why?
|
| Sex Factors | 2 | 2021 | 10619 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2024 | 3158 | 0.030 |
Why?
|
| Polymers | 1 | 2022 | 1624 | 0.030 |
Why?
|
| Blood Gas Monitoring, Transcutaneous | 1 | 2014 | 34 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 26310 | 0.030 |
Why?
|
| Hypothyroidism | 1 | 2020 | 665 | 0.030 |
Why?
|
| Disease Progression | 2 | 2022 | 13640 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2023 | 2391 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2021 | 9357 | 0.030 |
Why?
|
| Registries | 2 | 2021 | 8351 | 0.030 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2014 | 236 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2024 | 3227 | 0.030 |
Why?
|
| Diet | 1 | 2011 | 8088 | 0.030 |
Why?
|
| Cytoskeleton | 1 | 2018 | 1179 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2018 | 1674 | 0.030 |
Why?
|
| Cost Savings | 1 | 2018 | 902 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2024 | 4349 | 0.030 |
Why?
|
| Models, Animal | 1 | 2019 | 2121 | 0.030 |
Why?
|
| Tomography, Emission-Computed | 1 | 2014 | 1006 | 0.020 |
Why?
|
| Neoplasms | 1 | 2021 | 22350 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 39309 | 0.020 |
Why?
|
| Wine | 1 | 2011 | 172 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2021 | 1949 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2014 | 1374 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2018 | 2931 | 0.020 |
Why?
|
| Cacao | 1 | 2011 | 98 | 0.020 |
Why?
|
| Heparin | 1 | 2018 | 1636 | 0.020 |
Why?
|
| Adult | 4 | 2020 | 223307 | 0.020 |
Why?
|
| France | 1 | 2011 | 495 | 0.020 |
Why?
|
| Propensity Score | 1 | 2018 | 1972 | 0.020 |
Why?
|
| Asia | 1 | 2011 | 629 | 0.020 |
Why?
|
| Tea | 1 | 2011 | 289 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 2018 | 2053 | 0.020 |
Why?
|
| Cytokines | 1 | 2024 | 7438 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2018 | 2158 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 8540 | 0.020 |
Why?
|
| Linear Models | 1 | 2018 | 5874 | 0.020 |
Why?
|
| Young Adult | 3 | 2020 | 59939 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2019 | 1880 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2018 | 8307 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 7841 | 0.020 |
Why?
|
| Beverages | 1 | 2011 | 819 | 0.020 |
Why?
|
| Adolescent | 3 | 2020 | 88904 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2018 | 9661 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2021 | 3850 | 0.020 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 1946 | 0.020 |
Why?
|
| Ethanol | 1 | 2011 | 1326 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 3411 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 5536 | 0.010 |
Why?
|
| Health Status | 1 | 2018 | 4087 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2018 | 3465 | 0.010 |
Why?
|
| Diet, Mediterranean | 1 | 2011 | 746 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 12064 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2011 | 1806 | 0.010 |
Why?
|
| Survival Rate | 1 | 2018 | 12825 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 12534 | 0.010 |
Why?
|
| Logistic Models | 1 | 2018 | 13278 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2018 | 18984 | 0.010 |
Why?
|
| Incidence | 1 | 2021 | 21525 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2018 | 4855 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2018 | 12150 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2021 | 41710 | 0.010 |
Why?
|
| Child | 1 | 2018 | 80668 | 0.010 |
Why?
|